Cortex Pharmaceuticals, Inc.
Records under this name other than patents Cortex Pharmaceuticals, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Back to Cortex Pharmaceuticals, Inc.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,119,632 | Bicyclic amide derivatives for enhancing glutamatergic synaptic responses Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 8,642,633 | Di-substituted amides for enhancing glutamatergic synaptic responses Formerly held Lapsed on the fee record Ended Feb 4, 2026 · From the USPTO record | Lapsed on the fee record | Ended Feb 4, 2026 | From the USPTO record |
| US 8,507,482 | Bicyclic amide derivatives for enhancing glutamatergic synaptic responses Formerly held Lapsed on the fee record Ended Aug 13, 2025 · From the USPTO record | Lapsed on the fee record | Ended Aug 13, 2025 | From the USPTO record |
| US 8,404,682 | Di-substituted amides for enhancing glutamatergic synaptic responses Formerly held Lapsed on the fee record Ended Mar 26, 2025 · From the USPTO record | Lapsed on the fee record | Ended Mar 26, 2025 | From the USPTO record |
| US 9,492,440 | Bicyclic amides for enhancing glutamatergic synaptic responses Formerly held Lapsed on the fee record Ended Nov 15, 2024 · From the USPTO record | Lapsed on the fee record | Ended Nov 15, 2024 | From the USPTO record |
| US 8,263,591 | Bicyclic amides for enhancing glutamatergic synaptic responses Formerly held Lapsed on the fee record Ended Sep 11, 2024 · From the USPTO record | Lapsed on the fee record | Ended Sep 11, 2024 | From the USPTO record |
| US 8,173,644 | 3-substituted-[1,2,3]-benzotriazinone compound for enhancing glutamatergic synaptic responses Formerly held Lapsed on the fee record Ended May 8, 2024 · From the USPTO record | Lapsed on the fee record | Ended May 8, 2024 | From the USPTO record |
| US 8,168,632 | Bicyclic Amide Derivatives for the Treatmet of Respiratory Disorders Formerly held Lapsed on the fee record Ended May 1, 2024 · Low confidence | Lapsed on the fee record | Ended May 1, 2024 | Low confidence |
| US 8,013,003 | Di-Substituted Amides for Enhancing Glutamatergic Synaptic Responses Formerly held Lapsed on the fee record Ended Sep 6, 2023 · High confidence | Lapsed on the fee record | Ended Sep 6, 2023 | High confidence |
| US 8,110,584 | Methods for the Treatment of Respiratory Depression Formerly held Lapsed on the fee record Ended Feb 7, 2020 · Medium confidence | Lapsed on the fee record | Ended Feb 7, 2020 | Medium confidence |